Evaluation of BRUDYGLAUCO (DHA + Citicoline) in Patients With Glaucoma

Condition(s) studied

Investigational drug(s) / intervention(s)

BrudyGlauco: Participants in the experimental group will receive BrudyGlauco, a dietary supplement containing docosahexaenoic acid (DHA) and citicoline.

Placebo: Participants in the placebo comparator group will receive identical-looking capsules containing sunflower oil.

Study summary

This study aims to evaluate the effects of BrudyGlauco, a nutritional supplement containing DHA (docosahexaenoic acid) and citicoline, on visual function in people with glaucoma. Glaucoma is a progressive optic neuropathy that can lead to vision loss. Current treatments focus on lowering eye pressure, but there are other pathogenic factors and the use of additional therapies that could protect or regenerate the optic nerve would be beneficial.

This is a randomized, double-blind, placebo-controlled, and multicenter clinical trial. Participants will be randomly assigned to receive either BrudyGlauco or a placebo for 12 months. The study will assess changes in visual field, safety, and treatment adherence.

The trial is being conducted at the Institut Català de Retina (ICR) and Hospital de la Esperanza. Participants will undergo regular eye exams, visual field tests, and follow-ups to monitor potential improvements in visual function.

The results of this study will help determine if BrudyGlauco can provide neuroprotective benefits for people with glaucoma and improve their quality of life.

Eligibility

Primary outcome measure(s)

• Change from baseline in visual function assessed by Mean Deviation (MD) at 12 months — 12 months
  Change from baseline in visual function assessed by Mean Deviation (MD) at 12 months
• Change from baseline in visual function assessed by Visual Field Index (VFI) at 12 months — 12 months
  Change from baseline in visual function assessed by Visual Field Index (VFI) at 12 months

Trial sites (2)

Other trials for the same condition